Purpose: Inotropes and vasopressors are cornerstone of therapy in septic shock, but search for the best agent is ongoing. We aimed to determine which vasoactive drug is associated with the best survival. Materials and methods: PubMed, BioMedCentral, Embase, and the Cochrane Central Register were searched. Randomized trials performed in septic patients with at least 1 group allocated to an inotrope/vasopressor were included. Network meta-analysis with a frequentist approach was performed. . Rank analysis showed that levosimendan had the highest probability of being the best treatment. Conclusions: Among several regimens for pharmacological cardiovascular support in septic patients, regimens based on inodilators have the highest probability of improve survival.
Introduction
Severe sepsis is widely recognized as a major health issue. It occurs in up to one third of patients admitted to an intensive care unit (ICU) [1] and has an estimated incidence of up to 19 million in the world [2] , and its incidence is still raising [3, 4] . Although mortality rate in developed countries decreased in recent years, it remains as high as 20% to 30% [1, 3, 5] and may reach 40% in septic shock [3] .
Early hemodynamic stabilization is important in the management of septic patients. International guidelines recommend to administer intravenous fluids and, when volume replacement is not sufficient to restore adequate tissue perfusion, to add vasoactive agents [6] . Norepinephrine and dobutamine are currently the recommended first-line vasoactive drugs [6] ; however, use of other agents such as dopamine, epinephrine, phenylephrine, vasopressin, or terlipressin has also been investigated, and the search for the best agent is still ongoing [7] [8] [9] [10] [11] . Each drug has different pharmacological effects, with a unique theoretical profile of advantages and disadvantages [12] . Notably, in recent years, inodilators have also been frequently tested in patients with septic shock with the aim to improve cardiac function, which is often compromised in severe sepsis even in patients with no previous cardiac disease [13] . Inodilators may correct several cardiac and hemodynamic alterations associated with septic shock [13] . However, their vasodilating effect may also impair tissue perfusion by excessively lowering mean arterial pressure (MAP).
Although several randomized trials exist, most of them are small and compare only 2 agents [14] . A network meta-analysis is a statistical technique that allows an indirect comparison between treatments that have never been investigated one against the other in randomized clinical trials [15, 16] . There are currently no meta-analyses which compare vasoactive drugs in septic shock including also inodilators. Therefore, we performed a network meta-analysis to indirectly compare and grade all the vasoactive drugs ever tested in randomized controlled trials (RCTs) in septic patients to identify the treatment associated with the highest survival rate.
Material and methods
This work was designed as a systematic review and network metaanalysis, with reporting following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement [17] [18] [19] [20] (Preferred Reporting Items for Systematic Reviews and Meta-Analysis-Network Meta-Analyses Checklist available as Supplementary Material). End point of our study was mortality at the longest follow-up available.
Data sources and searches
Two investigators independently searched relevant studies on PubMed, Embase, BioMed Central, and the Cochrane Central register. Our aim was to find all RCTs testing an inotrope or a vasopressor (regardless of the molecule type) vs any type of control (including other drugs, placebo, or standard treatment without placebo) performed in the setting of sepsis. Literature search was last updated June 30, 2015 , and the full PubMed search strategy, modified from Biondi-Zoccai et al. [21] , is available in the Supplementary Material. In addition, when other meta-analyses, systematic reviews, or RCTs were found, we used backward snowballing (ie, scanning of references of retrieved articles and pertinent reviews) to obtain further studies.
Study selection
Investigators first examined references at a title/abstract level, with divergences resolved by consensus, and then, if potentially pertinent, retrieved the complete articles. Articles were included in the metaanalysis if they fulfilled the following inclusion criteria: random allocation to treatment, at least 1 group randomized to receive an inotrope or a vasopressor agent, and patients with sepsis. We applied no restriction in the type of control treatment (eg, other vasoactive agents, placebo, or standard treatment), severity of sepsis (sepsis, severe sepsis, or septic shock), or setting of treatment. We excluded trials performed in settings other than sepsis, studies investigating nonadult population, studies on overlapping population (ie, secondary analyses of a previously published trial), studies not reporting mortality data, studies published as abstract only, and animal studies. We also decided to exclude studies investigating drugs currently not available on the market either in Europe or in the United States.
Data extraction and quality assessment
Baseline, procedural, outcome, and follow-up data were independently abstracted by 2 investigators. Patients randomized to placebo and standard treatment were aggregated as a single comparison group. In cases of trials randomizing patients with different types of shock [7, 8] , only data from patients with septic shock were abstracted. Data were analyzed according to the intention-to-treat principle whenever possible. The internal validity and risk of bias of included trials were appraised by 2 independent investigators according to the "risk of bias assessment tool" developed by the Cochrane collaboration [22] . Briefly, for each trial, 7 domains were assessed: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data reporting, selective reporting, and presence of other bias. Presence of possible source of bias in each domain was assessed, and a final judgment of low, moderate, or high risk of bias was assigned.
Data synthesis and analysis
Dichotomous variables were reported as percentages, whereas continuous variables were reported as mean ± standard deviation or median (interquartile range). Network meta-analysis with a frequentist approach was used to compare mortality at the longest follow-up available between different therapies using the netmeta R package version 8.0 (available at: http://CRAN.R-project.org/package=netmeta) to calculate point estimates of odds ratios (ORs) with 95% confidence intervals (CIs) and generate head-to-head comparison and forest plots using random-effects models comparing the effect estimates of different therapies relative to placebo [23] . P rank scores were generated to determine probability scores to rank which therapies result in the lowest in-hospital mortality. Heterogeneity and inconsistency were assessed, and heat plots were also generated which are a matrix visualization proposed by Krahn and colleagues [24] that highlights hot spots of inconsistency between specific direct evidence in the whole network and renders transparent possible drivers. In addition, small study effects were appraised by visual inspection of adjusted funnel plots. Once the results of the network meta-analysis were obtained, we also performed an unplanned, traditional meta-analysis to compare the effect of levosimendan vs dobutamine on mortality. Details on the analysis methods for the traditional meta-analysis are provided in the Supplementary Material. Statistical analysis was performed using Stata 13 (StataCorp, College Station, TX), R [25] , and RevMan (Review Manager version 5.3; The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark), with statistical significance for hypothesis testing set at the .05 two-tailed level and for heterogeneity testing at the .10 two-tailed level.
Role of the funding source
This work was not supported by any specific funding source.
Results

Study characteristics
A total of 467 studies were identified through database search, and a total of 61 manuscripts were retrieved as complete article. Of these, 28 were excluded because of prespecified criteria (a list of excluded studies, together with reason for exclusion, is presented in Supplementary Table 1 [7] [8] [9] [10] [11] . Three studies randomized patients to 3 groups [10, 46, 49] , whereas all the others compared only 2 groups. Five studies were multicenter trials [7] [8] [9] 27, 34] .
The most frequently investigated comparators were norepinephrine (1218 patients, 13 studies) [7] [8] [9] [10] [11] 26, 31, 34, [39] [40] [41] 47, 48] , dopamine (1141 patients, 8 studies) [7, 30, [39] [40] [41] [47] [48] [49] , vasopressin (424 patients, 5 studies) [9, 10, 34, 36, 38] , epinephrine (302 patients, 6 studies) [8, 27, 35, 37, 49, 50] , combination of norepinephrine plus dobutamine (195 patients, 3 studies) [27, 35, 50] , and dobutamine (129 patients, 6 studies) [28, 32, 37, 42, 44, 45] (Fig. 2) .
The longest follow-up varied among different studies. The most frequently reported follow-up was ICU stay in 14 studies [10, 11, 29, 31, 32, 34, 36, 39, 41, 42, 46, 48, 50] followed by 28 or 30 days in further 14 studies [7] [8] [9] 27, 28, 30, 33, 37, 44, 47, 49, [51] [52] [53] and 90 days in 5 studies [9, 10, 27, 51, 52] .
Trials were on average of moderate quality, with a total of 10 studies judged to carry a low risk of bias, 21 a moderate risk of bias, and 2 a high risk of bias (Supplementary Material). This limitation should be viewed in light of the reliance on all-cause mortality, which is less prone to adjudication and attrition bias.
Quantitative data synthesis
Overall, 16 active treatments along with placebo were tested in 33 RCTs identified (Fig. 1, Table 1 ). A total of 39 pairwise comparisons were finally available. Head-to-head comparison obtained by network meta-analysis is shown in Table 2 Rank analysis showed that among treatments found to be significantly associated with reduced mortality, levosimendan showed the highest probability to be the best (85%) followed by dobutamine (65%), the combination of norepinephrine plus dobutamine (64%), epinephrine (60%), and vasopressin (59%) ( Supplementary Fig. 2 in Supplementary Material).
Results of a traditional meta-analysis comparing levosimendan vs dobutamine showed no difference between the 2 agents in terms of mortality (risk ratio for levosimendan vs dobutamine, 0.78; 95% CI, 0.56-1.09; I 2 = 0%, with 4 studies included [28, 42, 44, 45] ) (Supplementary Fig. 3 in Supplementary Material).
There was no significant heterogeneity/inconsistency among comparisons investigated (I 2 = 0%; Q statistics P value whole network, P = .99; within designs, P = .99; between designs, P = .94). Heat plot showed mild inconsistency only among terlipressin vs vasopressin vs norepinephrine comparison. Finally, inspection of comparisonadjusted funnel plot did not disclose significant small study effects or publication bias ( Supplementary Fig. 4 in Supplementary Material).
Discussion
To the best of our knowledge, this is the largest meta-analysis ever performed on vasoactive drugs in septic patients. Furthermore, we compared for the first time therapeutic regimens including inodilator drug with regimens including inoconstrictors or pure vasoconstrictors. The most important finding of our study is that, among 16 different treatments or combination of treatments, inodilators such as levosimendan and dobutamine showed the highest probability of being the agents associated with the lowest mortality. These results are particularly interesting because our traditional view of hemodynamic management of septic shock has been recently challenged by several large RCTs [54] [55] [56] , whereas our understanding of the complex pathophysiology of septic cardiovascular dysfunction is increasing [13, 57] .
Hypotension is almost universally present in septic shock [58] , and administration of drugs with the potential of further lowering MAP may seem counterintuitive in this setting. The findings of our metaanalysis can be explained by hypothesizing that the coadministration of inodilators and vasoconstrictors improves microcirculatory perfusion. In recent years, the role of microcirculatory dysfunction in circulatory shock has been increasingly recognized [59, 60] , and there is growing evidence that sufficient cardiac output, MAP, and calculated systemic oxygen delivery may not imply adequate tissue perfusion [61, 62] . Inodilators have microcirculatory effect independent from those on macrocirculation [63, 64] . Furthermore, conventional hemodynamic resuscitation may not correct microcirculatory alterations [65] . On the contrary, excessive vasopressor administration and subsequent vasoconstriction could have a detrimental effect on the overall oxygen consumption/delivery balance [66] . With the combination of both cardiac output augmentation and peripheral vasodilation, inodilatory agents might be able to improve tissue oxygenation, which is the ultimate determinant of organ function, to a better extent than inoconstrictors alone.
Beneficial effects of inodilators on microcirculation were documented also in settings other than septic shock. Den Uil and colleagues [65] investigated the effect of enoximone, dobutamine, and norepinephrine on microcirculatory function in patients with acute myocardial infarction and cardiogenic shock. They found that enoximone has the most favorable effect on microcirculation, and patients with improved microcirculatory function have a higher probability of survival [65] . Pirracchio and colleagues [67] also investigated the effect of adding an inodilator to inoconstrictors in patients with cardiogenic shock, and their study suggested that inodilator administration may improve short-term mortality. However, the hemodynamic characteristics of septic and cardiogenic shock are different [58] , and this may limit the generalization of these results also to patients with septic shock. Among the different agents, we found that levosimendan has the highest probability of being the best in survival. This might be explained by the different mechanism of action and adverse effect profile of levosimendan as compared with dobutamine and other catecholamines [68] [69] [70] . All catecholamines increase myocardial oxygen consumption, increase heart rate, and can trigger arrhythmias. Furthermore, excessive adrenergic stimulation is associated to additional metabolic and immunological adverse effects [70] , and excessive levels of catecholamines are thought to be involved in the pathophysiology of septic cardiomyopathy [13, 71] . Compared with catecholamines, levosimendan does not stimulate adrenergic receptors, causes little increase in myocardial oxygen consumption, and may on the contrary have a cardioprotective effect [68, 69] . Furthermore, levosimendan improves diastolic function (a key element of septic cardiomyopathy [13] ) to a better extent than dobutamine [72] and improves ventriculoarterial coupling [57, 73] , another recently described aspect of impairment of left ventricular function due to sepsis [13, 57, 44, 45] . Of note, we found no difference in mortality when comparing levosimendan and dobutamine using both a network approach and a traditional meta-analysis, as already suggested by previous studies [74] . Nevertheless, we observed a small trend toward mortality reduction in the levosimendan group. Interestingly, although levosimendan underwent an extensive investigation in several RCTs [75] , no RCTs on dobutamine use in patients with sepsis have been published, although dobutamine is recommended as inotrope of choice by the Surviving Sepsis Campaign guidelines [6] , whereas levosimendan is not even mentioned. Hopefully, the ongoing Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis (ISRCTN12776039) multicenter RCT will answer the question of whether levosimendan administration improves organ function in patients with sepsis [76] .
Another important RCT which is going to provide further insights on the best hemodynamic treatment of septic shock is the Vasopressin Versus Noradrenaline as Initial Therapy in Septic Shock (ISRCTN20769191) trial, which investigated the effect of early administration of vasopressin and hydrocortisone using a 2 × 2 factorial design [77] . Results of this study are strongly awaited because previous meta-analyses [78, 79] and also our study of early vasopressin administration found that it was associated with improved survival in septic patients [80] .
As of today, supportive treatment of septic shock focused on administration of fluids and vasopressors in the first place, with the goal of maintaining an adequate MAP, with addition of inotropes and/or blood products if a sufficient tissue perfusion cannot be obtained or if evidences of cardiac dysfunction exist [6] . Dobutamine is currently the only inotrope recommended by guidelines, although with a low grade of evidence, whereas norepinephrine is suggested as first-line vasoconstrictor [6] . Since the landmark trial from Rivers et al. [81] , hemodynamic management of septic shock focused on parameters reflecting macrocirculatory function, that is, MAP, central venous pressure, and central venous oxygen saturation [6, 82] . However, several large, multicenter RCTs have recently challenged this traditional approach [54] [55] [56] . Although early diagnosis of sepsis and prompt antibiotic administration have been recognized to clearly improve outcome and have now entered routine clinical practice, the optimal approach to hemodynamic monitoring and management remains controversial. In every day clinical practice, MAP is often considered the most important hemodynamic parameter in patients with shock, as MAP lower than 60 to 65 mm Hg is associated with a poor outcome [61] . On the other side, it has been demonstrated that central venous pressure is a poor index of volume status [83] , and excessive fluid administration is detrimental [84] . Implementation of resuscitation protocols based on dynamic indices of fluid responsiveness could help to overcome these issues and allow a patient-targeted fluid administration [82] . In addition, devices capable of directly monitoring microcirculation and tissue oxygenation are now available [85] , and their use might further improve development of patient-specific treatment algorithms.
Oba and Lone [86] published a Bayesian network meta-analysis investigating the effect of inotropic and vasopressors agents in septic shock which included 14 studies randomizing a total of 2811 patients. They concluded that norepinephrine and the combination of norepinephrine plus low-dose vasopressin might improve survival as compared with dopamine alone. On the contrary, they found that addition of an inotropic agent to treatment did not reduce mortality.
Zhou et al. [87] recently published a network meta-analysis of 21 studies (3819 patients) investigating the effect of vasopressors in patients with septic shock. They concluded that norepinephrine may be superior to dopamine as a vasopressor in septic shock in patients' survival [87] . Compared with these 2 meta-analyses, we included a larger number of studies investigating a wider range of vasoactive agents. Furthermore, two of the studies [88, 89] included by Zhou et al. were actually substudies of a larger multicenter RCT [9] , artificially increasing the overall number of patients by 1019. Our results differ from those of previous meta-analyses because we included in our analysis a larger number of studies, investigating also inodilatory agents. Although we also found that norepinephrine may be superior to dopamine, as already suggested by other works [90, 91] , our most important finding is that addition of inodilators agents seems to be superior to treatment with vasopressors alone. Interestingly, in our study, norepinephrine was not associated with increased survival as compared with placebo/standard treatment. This should not surprise, as all patients randomized to "control" group also received the best available treatment, which includes norepinephrine or other vasoconstrictors (Supplementary Table 2 ).
Our study has some limitations. First of all, despite the large number of trials and patients included, most studies were small, single-center trials, putting them at high risk for biases [82, 83] . Another important limitation is the inclusion of a large number of treatments (16 treatments). Furthermore, we acknowledge that a few of included trials were relatively old and were published before the landmark trial of Rivers et al. [81] that had a strong impact on management of septic shock. However, we preferred to include these trials, as other authors did [86, 87, 90, 91] , to provide the most complete analysis possible with current evidence. Furthermore, the same limitations of traditional metaanalyses also apply to network meta-analyses [16] [17] [18] . In particular, meta-analyses should be viewed as hypothesis-generating tools rather than providing definitive evidences. Therefore, our results, although providing interesting insights on management of septic shock, should be confirmed with adequately designed and adequately powered multicenter randomized trials [92, 93] . Notably, hemodynamic management of septic shock is a complex issue involving not only vasoactive drugs but also fluids, and timing of intervention is also critical [94] . Future studies should focus on finding the best combination of fluids, vasopressors, and inotropes to achieve sufficient tissue perfusion rather than normal "gross" hemodynamic parameters, and we will likely move toward individualized rather than protocolized hemodynamic management [61, 95] . In addition, both short-and long-term follow-up should be reported [96] .
Conclusions
In patients with septic shock, use of inodilators is associated with the highest survival probability. Among 16 different treatment regimens, levosimendan is the most promising, followed by dobutamine and a combination of dobutamine plus norepinephrine. Nevertheless, available evidence is still insufficient to recommend such treatment because of lack of high-quality, multicenter RCTs. Future RCTs focusing on the role of inodilators in septic shock are warranted.
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